Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Hookipa Pharma Inc (HOOK)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Hookipa Pharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.7649 +0.0024    +0.31%
18/04 - Closed. Currency in USD ( Disclaimer )
Pre Market
0.8770
+0.1121
+14.6555%
9:16:10 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 168,816
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.7529 - 0.7999
Hookipa Pharma 0.7649 +0.0024 +0.31%

Hookipa Pharma Inc Company Profile

 
Get an in-depth profile of Hookipa Pharma Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

167

Equity Type

ORD

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company’s preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Contact Information

Address 350 Fifth Avenue 72nd Floor
Suite 7240 New York, 10118
United States
Phone 431 890 6360
Fax -

Top Executives

Name Age Since Title
Jean-Charles Soria 50 2020 Director
Jan G.J. van de Winkel 60 2017 Independent Chairman of the Board
Reinhard Kandera 52 2017 CFO & Director
Joern Aldag 62 2016 CEO & Director
Sander van Deventer 68 2011 Scientific Advisory Member
David Ross Kaufman 49 2019 Independent Director
Julie O'Neill 56 2018 Independent Non-Executive Director
Timothy Reilly 49 2022 Independent Non-Executive Director
Mary Theresa Coelho 61 2023 Independent Director
Malte Peters 62 2023 Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

HOOK Comments

Write your thoughts about Hookipa Pharma Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email